An observational study in Breast Cancer, sponsored by Sun Yat-sen University. Completed at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Sun Yat-sen University · Observational
The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is:
How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 597 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Advanced breast cancer taking metronomic chemotherapy
Exclusion Criteria:
Patients with advanced breast cancer who received metronomic chemotherapy.
Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
Progression free survival
Time from randomization to the first documentation of objective tumor progression or to death due to any cause without documented progression
Time frame: Baseline up to approximately 20 months
Overall Survival
Time from randomization to date of death due to any cause
Time frame: Baseline until death (up to approximately 40 months)
Objective Response Rate
Objective response is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from randomization until disease progression or death due to any cause.
Time frame: Baseline up to approximately 20 months
Disease Control Rate
Disease control is defined as complete response (CR), partial response (PR), or stable disease (SD) \>24 weeks according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death to any cause.
Time frame: Baseline up to approximately 20 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-sen University